Investor Relations
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>
Feb 04, 2019
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes MORE >>
Feb 01, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer MORE >>
Jan 31, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator MORE >>

SEC Filing Details

Document Details

Form
Filing Date
Feb 6, 2019
Document Date
Feb 6, 2019
Form Description
Form of prospectus filed in connection with primary offering of securities on a delayed basis
Filing Group
Registration Statements
Company
OPKO Health, Inc.